Zimmer Biomet Holdings – Consensus Indicates Potential 9.0% Upside
Zimmer Biomet Holdings found using ticker (ZBH) now have 20 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 145 and 114 calculating the average target price we see 131.55. With the stocks previous close at 120.65 this would imply there is a potential upside of 9.0%. There is a 50 day moving average of 123.11 and the 200 moving average now moves to 128.1. The company has a market capitalisation of $25,114m. Find out more information at: https:||www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,382m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Zimmer Biomet Holdings – Consensus Indicates Potential 9.0% Upside
Zimmer Biomet Holdings found using ticker (ZBH) now have 20 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 145 and 114 calculating the average target price we see 131.55. With the stocks previous close at 120.65 this would imply there is a potential upside of 9.0%. There is a 50 day moving average of 123.11 and the 200 moving average now moves to 128.1. The company has a market capitalisation of $25,114m. Find out more information at: https:||www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,382m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.